You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

Technology Transfer and Intellectual Property

The Office of Technology Transfer is responsible for identifying clinically or commercially significant research activities arising at Baystate, ensuring that such developments are protected via the most appropriate route (e.g. patents, copyrights, etc.), and working with industry to promote the development of beneficial products from Baystate's research and inventions.

Technology Transfer Officer

Todd Keiller, MBA

Office: 508-395-4221

Products on the Market

Products on the Market

Several Baystate-developed technologies are already on the market and are being made commercially available by our licensees. 

Solution to Pyschological Insulin Resistance (SPIR)

The SPIR program is conceptualized as an integrated patient and provider assessment and treatment program to overcome the clinical problem of Psychological Insulin Resistance and improve evidence-based insulin management for diabetes in primary care clinics within a comprehensive diabetes care model. This program is the culmination of years of research by Baystate investigator, Gary Welch, Ph.D

Silver Fern Healthcare, LLC
11 Northmoor Road
West Hartford, CT 06117

Improved Devices for Natural Orifice Translumenal Endoscopic Surgery (NOTES)

Dr. David Desilets of Baystate has developed and tested two innovative surgical devices for use in Natural Orifice Translumenal Endoscopic Surgery (NOTES), both of which were jointly invented with engineers at a well-known surgical device company. Baystate has entered into license agreements with this company for the development and commercialization of these devices.

Exclusive license to surgical device company.

Integrated Dynamic GIS Mapping Extension for Medical Crisis Information Management System

Baystate, through its for-profit off-shoot Baystate Health Geographics, has collaborated with Global Emergency Resources, Inc. to create an improved Medical Crisis Information Management System (M-CIMS).

This new system integrates M-CIMS with dynamic Geographical Information Systems (GIS) technology to provide healthcare disaster managers with access to the right information, in the right format and at the right time, to create an “infosphere of healthcare preparedness” at the national, regional, state, local or institutional level.

This system has been incorporated into Global Emergency Resources’ product HC Standard, which is the first truly specialized web-based Medical Crisis Information Management Software. Baystate Health Geographics is internationally recognized for “pushing the GIS envelope” in the areas of hospital healthcare and “hospital-land” security.

Global Emergency Resources
2910-B Professional Parkway
Augusta, GA 30907
phone 866-404-6911

Inventions for License

Inventions for License

Baystate maintains a portfolio of pending patent applications and other inventions that are available for licensing to for-profit companies.

Balloon Endoscope Device

Invention: BH-005 | Inventor: Jerry Khachi, MD

An improved tool for endoscopic surgery that provides the surgeon with greater maneuverability and powerful dissection capabilities, particularly useful for surgeries involving small incisions.

Assays for Detecting and Identifying Agents for Treating Male Infertility

Invention: BH-012 | Inventor: Daniel Grow, MD, Teru Jellerette, PhD

A potential diagnostic test to detect male infertility in sperm samples, based on the discovery that the protein phospholipase C-zeta may be the factor in sperm that determines success of fertilization and egg activation.

Method for Determining the Presence of Mutated BRCA Protein

US Patent No. 5,965,377 | Inventor: Gabriel Cohn, MD

A potential new diagnostic assay to determine a woman’s likelihood of incurring breast cancer. The assay is based on the use of antibodies to detect the truncated forms of the BRCA1 and BRCA2 proteins that are known to correlate to increased risk of breast and ovarian cancer. The test is expected to be less expensive than current genetic tests for BRCA mutations, thus broadening the population of women who might benefit from the diagnostic test.